News
Nipocalimab, a neonatal Fc receptor (FcRn) blocker, is under development for the treatment of multiple IgG autoantibody- or alloantibody-driven diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback